In an Australian phase II trial (COALITION), researchers investigated the addition of glofitamab to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) as first-line therapy in patients aged ≤ 65 with high-risk large B-cell lymphoma (LBCL).
Patients with ovarian clear cell carcinoma harboring PPP2R1A mutations may achieve greater benefit from immunotherapy than those without these mutations, study findings suggest.
Certain chemotherapy agents may impact the mutational burden and cell population structure of normal tissue and blood cells, study results showed.
|